HAYA Therapeutics Secures $1 Billion in Seed Round Funding for Innovative RNA-guided Therapeutics

HAYA Therapeutics, a leader in precision medicines, has successfully raised $1 billion to further its groundbreaking work in RNA-guided programmable therapeutics. This substantial funding will significantly enhance the company's efforts to uncover novel therapeutic advancements targeting the regulatory genome, particularly for serious health conditions such as cardiovascular disease and cancer. Utilizing its innovative cell-state modifying platform, HAYA Therapeutics aims to unlock the potential of long non-coding RNAs (lncRNAs), often referred to as the ‘dark genomes’ of biology. At the forefront of their pipeline is HTX-001, an antisense oligonucleotide specifically designed to target Wisper, a cardiac lncRNA instrumental in heart failure. Beyond its lead candidate, HAYA is poised to expand its suite of lncRNA-targeting therapeutics for cell-specific treatments across various tissues, including the lungs and the microenvironments of solid tumors. With its headquarters located in Biopôle, Lausanne, Switzerland, and laboratory facilities at JLABS @ San Diego, HAYA Therapeutics is strategically positioned to leverage a wealth of expertise within the realm of RNA-targeted therapeutics. Guided by a team of seasoned professionals, the company is supported by a robust investor consortium, underlining investor confidence in its mission to develop next-generation disease-modifying therapeutics. This landmark funding not only propels HAYA’s vision forward but also reinforces its commitment to delivering innovative and effective treatments with enhanced efficacy and safety compared to existing options, ultimately striving for greater accessibility for patients worldwide.